weight loss glp-1 agonists Comparing Ozempic, Wegovy and Other Drugs Part 2 of a 3-Part

It has shown significant promise as an effective intervention against type 2 diabetes (T2D) and excessive body weight, resulting in the United States Food and Drug Administration (FDA) approving its use against both conditions in May 2022 for T2D and November 2023 for obesity

Back Lay, K (28 March 2024) 'Study: 'gamechanger' diabetes drugs cost up to 400 times more than needed', The Guardian

Gastrointestinal disorders, primarily nausea, were the most common treatment-emergent adverse events, which could be mitigated with slower dose escalation

Cell Tissue Res 192: 227-240, 1978

In the STEP 1 trial extension, 327 participants were assessed for one year after discontinuing semaglutide 2.4 mg and lifestyle intervention

Therefore, the results from the FAERS database should be interpreted with caution as they can overestimate adverse events due to reporting bias and do not establish causality